Repaglinide

Repaglinide

SCHEMBL16137

CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC8KCNJ11

The experimentally established mechanism targets of Repaglinide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC8 known ✓ Q09428 3/20 1.00
LMNA P02545 3/20 1.00
MAPK1 P28482 2/20 1.00
CYP3A4 P08684 2/20 1.00
SLC22A1 O15245 1/20 1.00
ABCC3 O15438 1/20 1.00
ABCC4 O15439 1/20 1.00
NR1I2 O75469 1/20 1.00
ABCB11 O95342 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
HTR2A P28223 1/20 1.00
ADRA1A P35348 1/20 1.00
PTGS2 P35354 1/20 1.00
PDE4D Q08499 1/20 1.00
NR1I3 Q14994 1/20 1.00
ABCC2 Q92887 1/20 1.00
NR1H4 Q96RI1 1/20 1.00
GAA P10253 3/20 0.44
GFER P55789 1/20 0.44
KCNQ2 O43526 5/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Repaglinide SCHEMBL29373506 1.00 ABCC8 (1.00) ABCC8LMNAMAPK1CYP3A4SLC22A1
Repaglinide SCHEMBL29392295 1.00 ABCC8 (1.00) ABCC8LMNAMAPK1CYP3A4SLC22A1
Repaglinide SCHEMBL8141950 1.00 ABCC8 (1.00) ABCC8LMNAMAPK1CYP3A4SLC22A1
Repaglinide SCHEMBL29598841 1.00 ABCC8 (1.00) ABCC8LMNAMAPK1CYP3A4SLC22A1
Repaglinide SCHEMBL1536902 1.00 ABCC8 (1.00) ABCC8LMNAMAPK1CYP3A4SLC22A1
Repaglinide SCHEMBL163867 1.00 ABCC8 (1.00) ABCC8LMNAMAPK1CYP3A4SLC22A1
Repaglinide SCHEMBL6240747 0.99 ABCC8 (0.98) ABCC8LMNAMAPK1CYP3A4SLC22A1
Repaglinide SCHEMBL29085555 0.99 ABCC8 (0.98) ABCC8LMNAMAPK1CYP3A4SLC22A1
Repaglinide SCHEMBL6240755 0.99 ABCC8 (0.98) ABCC8LMNAMAPK1CYP3A4SLC22A1
Repaglinide SCHEMBL27961819 0.99 ABCC8 (0.98) ABCC8LMNAMAPK1CYP3A4SLC22A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 36507 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124282-A1 DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) 2026-05-07 US claimed
US-20260115210-A1 METHOD FOR TREATING SUBJECTS SUFFERING FROM CENTRAL NERVOUS SYSTEM CONTUSIONS REMEDY PHARMACEUTICALS, INC. (US) 2026-04-30 US claimed
US-12611416-B2 Methods of treating ischemic stroke at risk for cerebral or cerebellar edema REMEDY PHARMACEUTICALS, INC. (US) 2026-04-28 US claimed
US-12599564-B2 Antidiabetic pharmaceutical compositions Elite Pharmaceutical Solution Inc. (US) 2026-04-14 US claimed
US-20260097039-A1 METHODS FOR TREATING A FATTY LIVER DISEASE MADRIGAL PHARMACEUTICALS INC (US) 2026-04-09 US claimed
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2026-03-26 US claimed
US-20260069550-A1 TRANSDERMAL DELIVERY OF ANTIDIABETIC AGENTS RITTENHOUSE CHRISTINE (US) 2026-03-12 US claimed
EP-4705280-A1 DIARYL UREA-BASED COMPOUNDS AND RELATED COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DIABETES MELLITUS AND NEURODEGENERATIVE DISEASE Purdue Research Foundation (US) 2026-03-11 EP claimed
EP-4684799-A2 ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF TrueBinding, Inc. (US) 2026-01-28 EP claimed
US-12527754-B2 Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions TUFTS MEDICAL CENTER, INC. (US) 2026-01-20 US claimed
EP-0589874-B1 USE OF (S)(+)-2-ETHOXY-4-[N-[1-(2-PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYLMETHYL]BENZOIC ACID FOR THE PREPARATION OF A LONGLASTING ANTIDIABETIC MEDICAMENT BOEHRINGER INGELHEIM PHARMA (DE) 1999-09-08 EP claimed
WO-1999043708-A1 GLP-1 DERIVATIVES OF GLP-1 AND EXENDIN WITH PROTRACTED PROFILE OF ACTION NOVO NORDISK A/S (DK) 1999-09-02 WO claimed
WO-1999003478-A1 TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND ALPHA GLUCOCIDASE INHIBITOR SMITHKLINE BEECHAM P.L.C. (GB) 1999-01-28 WO claimed
WO-1999003476-A1 TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE AND SULPHONYLUREA SMITHKLINE BEECHAM PLC (GB) 1999-01-28 WO claimed
WO-1999003477-A1 TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND DIGUANIDE SMITHKLINE BEECHAM P.L.C. (GB) 1999-01-28 WO claimed
WO-1998056378-A1 NOVEL NIDDM REGIMEN NOVO NORDISK A/S (DK) 1998-12-17 WO claimed
WO-1998022114-A1 A METHOD FOR PROMOTING TISSUE REPAIR DUMEX-ALPHARMA A/S (DK) 1998-05-28 WO claimed
US-5631224-A ANTIDIABETIC AGENTS NOVO NORDISK A/S (DK) 1997-05-20 US claimed
US-5349100-A Chiral metallocene compounds and preparation thereof by creation of a chiral center by enantioselective hydride transfer EXXON CHEMICAL PATENTS INC. (US) 1994-09-20 US claimed
WO-1992012112-A1 CHIRAL METALLOCENE COMPOUNDS AND PREPARATION THEREOF BY CREATION OF A CHIRAL CENTER BY ENANTIOSELECTIVE HYDRIDE TRANSFER EXXON CHEMICAL PATENTS INC. (US) 1992-07-23 WO claimed